News and Events
Stay up to date with news and events
Hunting for balance: how the huntingtin protein compensates in HD
A group led by Dr. Sandrine Humbert from the French National Institute for Health and Medical Research published new work in the prestigious journal Science….
Roche Phase II GENERATION HD2 study underway
Roche released a community letter last month, detailing how their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. Learn more…
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment…
Map-HD Registry has the first 100 participants!
Thank you to each and every person who signed up! Read the full article here.
uniQure gets the green light to resume testing HD gene therapy
In August 2022, uniQure announced a pause in new recruitment for their trial of AMT-130, an HD gene therapy delivered via brain surgery. The decision…